ABSTRACT NUMBER: ESOC2026A1342 DOES DORNASE ALPHA POTENTIATE CLOT LYSIS WITH TENECTEPLASE? INSIGHTS FROM EX-VIVO LYSIS OF THROMBECTOMY CLOTS

作者：O. Swarup, A. Balabanski, Joanne Chia, Zikou Liu, Tammy Lam, Geoffrey C. Cloud, Bruce C Campbell, R. Medcalf · 发表于：European Stroke Journal · 年份：2026 · DOI：10.1093/esj/aakag023.647

Abstract Background and aims Dornase-alpha, a recombinant human deoxyribonuclease-I, can potentiate alteplase-mediated clot lysis via breakdown of neutrophil extracellular traps in stroke clots. We aimed to determine if dornase potentiates clot lysis in combination with tenecteplase ex-vivo in thrombectomy clots retrieved from stroke patients. Methods Forty-two thrombectomy clots were divided and suspended in buffer, pooled citrated or heparinised plasma and incubated with 15nM tenecteplase or in combination with either 10U/ml or 100U/ml of dornase. Clot weight was measured over 120-minutes, and treated clots underwent immunofluorescence. Statistical significance was assessed using linear mixed-effects modelling. Results Addition of tenecteplase to retrieved clots in buffer resulted in a median percentage reduction to 40.7% (IQR:17.0-53.7%) of the initial clot weight after 120-minutes. The addition of 100U/ml of dornase led to significant clot weight reduction to 17.5% (IQR:8.8-27.2%) while the addition of 10U/ml of dornase led to a non-significant reduction to 28.0% (IQR:7.4-45.7%) compared to tenecteplase alone. Further, incubation in citrated and heparinised plasma resulted in a clot weight reduction to 55.7% (IQR:21.6-70.7) and 58.5% (IQR:45.3-73.2) in the presence of tenecteplase respectively, with a non-statistically significant reduction with addition of Dornase. However, there was a significant attenuation in clot weight reduction in plasma compared to buffer in clots...